Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis B vaccine recombinant (GSK)
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The hepatitis B vaccine recombinant (marketed as Engerix-B by GSK) is a noninfectious, recombinant DNA vaccine indicated for immunization against infection caused by all known subtypes of the hepatitis B virus. The active ingredient is the hepatitis B surface antigen (HBsAg), which is produced in yeast cells (Saccharomyces cerevisiae) using recombinant DNA technology. The purified HBsAg assembles into spherical particles and is adsorbed onto aluminum hydroxide as an adjuvant to enhance immunogenicity. Upon administration, the vaccine induces specific humoral antibodies against HBsAg (anti-HBs antibodies). An anti-HBs antibody titre above 10 IU/L correlates with protection from HBV infection. More than 90% of healthy adults and children develop protective antibody levels after completing the primary vaccination schedule[2][3][4][5][7].
- Brand names
- Engerix-B
- Other names
- hepatitis B vaccine recombinantHepatitis B Vaccine (Recombinant)ENGERIX-BGSK HBsAg vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on hepatitis B vaccine recombinant (GSK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis B vaccine recombinant (GSK).